Clinical Trials Logo

Citation(s)

  •   Cherian JJ, Barrington J, Elmallah RK, Chughtai M, Mistry JB, Mont MA
    Liposomal Bupivacaine Suspension, Can Reduce Length of Stay and Improve Discharge Status of Patients Undergoing Total Hip Arthroplasty. Surg Technol Int. 2015 Nov;27:235-9.
  •   Hu D, Onel E, Singla N, Kramer WG, Hadzic A
    Pharmacokinetic profile of liposome bupivacaine injection following a single administration at the surgical site. Clin Drug Investig. 2013 Feb;33(2):109-15. doi: 10.1007/s40261-012-0043-z. Review.
  •   Jonnavithula N, Pisapati MV, Durga P, Krishnamurthy V, Chilumu R, Reddy B
    Efficacy of peritubal local anesthetic infiltration in alleviating postoperative pain in percutaneous nephrolithotomy. J Endourol. 2009 May;23(5):857-60. doi: 10.1089/end.2008.0634.
  •   Lojanapiwat B, Chureemas T, Kittirattarakarn P
    The efficacy of peritubal analgesic infiltration in postoperative pain following percutaneous nephrolithotomy - A prospective randomized controlled study. Int Braz J Urol. 2015 Sep-Oct;41(5):945-52. doi: 10.1590/S1677-5538.IBJU.2014.0471.
  •   Marcet JE, Nfonsam VN, Larach S
    An extended paIn relief trial utilizing the infiltration of a long-acting Multivesicular liPosome foRmulation Of bupiVacaine, EXPAREL (IMPROVE): a Phase IV health economic trial in adult patients undergoing ileostomy reversal. J Pain Res. 2013 Jul 18;6:549-55. doi: 10.2147/JPR.S46467. Print 2013.
  •   Vogel JD
    Liposome bupivacaine (EXPAREL®) for extended pain relief in patients undergoing ileostomy reversal at a single institution with a fast-track discharge protocol: an IMPROVE Phase IV health economics trial. J Pain Res. 2013 Jul 29;6:605-10. doi: 10.2147/JPR.S46950. Print 2013.

Efficacy of Liposomal Bupivacaine for Pain Control After Percutaneous Nephrostolithotomy

Details for clinical trial NCT03043027